References
- 1. Parkin, D.M., Bray, F., Ferlay, J. & Pisani, P. (2005). Global cancer statistics, 2002. CA: Cancer J Clin. 55, 74-108
- 2. Dudek, A.Z. & Mahaseth, H. (2005). Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 23, 193 - 200
- 3. Bremnes, R.M., Camps, C. & Sirera, R. (2006). Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumors and blood. Lung Cancer. 51, 143-58
- 4. Tanaka, F., Otake, Y. & Yanagihara, K. et al. (2001). Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 7, 3410 - 3415
- 5. Sun, S. & Schiller, J.H. (2007). Angiogenesis inhibitors in the treatment of lung cancer. Clinical Reviews in Oncology/Hematology. 62, 93-104
- 6. Folkman, J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol. 3, 65-71
- 7. Kerbel, RS. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21, 505-515
- 8. Macchiarini, P., Fontanini, G. & Hardin, M.J. et al. (1992). Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 340, 145-56
- 9. Traweek, S.T., Kandalaft, P.L., Mehta, P. & Battifora, H. (1991). The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am. J. Clin. Pathol. 96, 25-31
- 10. Kuzu, I., Bicknell, R., Harris, A.L., Jones, M., Gatter, K.C. & Mason, D.Y. (1992). Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumors. J. Clin. Pathol. 45, 143-148
- 11. Martin, L., Holcombe, C., Green, B., Leinster, S.J. & Winstanley, J. (1997). Is a histological section representative of whole tumor vascularity in breast cancer? Br. J. Cancer. 76, 40-43
- 12. Weidner, N., Semple, J.P., Welch, W.R. & Folkman, J. (1992). Tumor angiogenesis and metastasis correlation in invasive breast cancer. N. Engl. J. Med. 324, 1-8
- 13. De Jong, J.S., Van Diest, P.J. & Baak, J.P.A. (1995). Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab. Invest. 73, 992-996
- 14. Vieira, S.C., Silva, B.B., Pinto, G.A., Vassallo, J., Moraes, N.G., Santana, J.O.I., Santos, L.G., Carvasan, G.A.F. & Zeferino, L.C. (2005). CD34 as a marker for evaluating angiogenesis in cervical cancer. Pathology - Research and practice. 201, 313-18
- 15. Barbareschi, M., Weidner, N. & Gasparini, G. (1995). Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. computer-aided image analysis system. Appl. Immunohistochem. 2, 75-84
- 16. Vermeulen, P.B., Verhoeven, D., Fierens, H., Hubens, G., Goovaerts, G., Van Marck, E., De Bruijn, E.A., Van Oosterom, A.T. & Dirix, L.Y. (1995). Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study. Br. J. Cancer. 71, 340-343
- 17. Meert, A.P, Paesmans, M. & Martin, B. et al. (2002). The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with metaanalysis. Br J Cancer. 87, 694-701
- 18. Johnson, D.H., Fehrenbacher, L. & Novotny, W.F. et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 22, 2184-2191
- 19. Kadota, K., Huang, C., Liu, D., Ueno, M., Kushida, Y., Haba, R. & Yokomise, H. (2008). The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. European Journal of Cancer. 44, 1057-1067